FindTrial
Sign In

Clinical application value and criteria of CBBCT in breast cancer response evaluation

Clinical application value and criteria of CBBCT in breast cancer response evaluation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030909
Enrollment
Unknown
Registered
2020-03-17
Start date
2019-03-15
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mammary cancer

Interventions

1:CBBCT Scan
2:US, MG and/or MRI

Sponsors

Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. female, breast cancer patient; 2. plan to accept neoadjuvant therapy, and promise to complete all treatment and the follow-up in our hospital; 3. can provide the ultrasound and breast magnetic resonance examination results from our hospital within two weeks before and after the CBBCT scan; 4. can complete the CBBCT scans with prone position.

Exclusion criteria

Exclusion criteria: 1) pregnant or suspicious of being pregnant; 2) received chest radiotherapy in the past; 3) takes part in other radiation-related studies within one month; 4) has contraindications for use of iodine contrast agent, such as iodine contrast agent allergy, hyperthyroidism, etc.

Design outcomes

Primary

MeasureTime frame
max diameter of lesion;—

Countries

China

Contacts

Public ContactYAO-PAN WU

Sun Yat-sen University Cancer Center

wuyp@sysucc.org.cn+86 13711155608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026